Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Co-Founder Pete Nicholas Dies

Executive Summary

Nicholas co-founded Boston Scientific in 1979 with John Abele. He served as the company’s CEO from 1979 until 1999 and as chairman until 2016.

You may also be interested in...

Earl Bakken, Medtronic Co-Founder And CRM Pioneer, Dies

Medtronic co-founder and cardiac rhythm management pioneer, Earl Bakken, passed away Oct. 21 at his home in Kiholo, Hawaii at age 94.

Boston Scientific board reshuffle as Nicholas retires

Boston Scientific co-founder Pete Nicholas is retiring and stepping down as chairman in May. Current CEO Michael Mahoney will step into Nicholas’ shoes and take on the additional role as head of the board.

Guidant’s Problems Go Beyond Bad Communication – Boston Scientific CEO

Boston Scientific will overhaul product design at recently acquired Guidant to prevent the recurrence of malfunctioning pacemakers and implantable defibrillators

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts